Recent Updates
Recently added Catalysts
OLMA Positive Sentiment

Olema Oncology to Participate in Upcoming Investor Conferences

Key Takeaway: Olema Oncology announced its participation in three upcoming investor conferences in late November and early December 2026. The events include the Evercore Healthcare Conference, Citi's Global Healthcare Conference, and Piper Sandler's Healthcare Conference. The company aims to discuss its advancements in targeted therapies for breast cancer, including its lead candidate, palazestrant, currently in Phase 3 trials.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in multiple investor conferences
  • Focus on targeted therapies for breast cancer
  • Lead product candidate in Phase 3 trials
  • Development of innovative cancer therapies

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+84%
120-day peak, hindsight
Typical move
4%
average across 6 past catalysts
Cash runway
~26 mo
Minimal dilution risk
Lead asset
Palazestrant
Phase 3 · Breast Cancer

Full Press Release Details

SAN FRANCISCO, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Olema Oncology, Inc. (“Olema,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences:

9th Annual Evercore Healthcare Conference Date and Time: November 30, 2026 at 2:35 p.m. ET Format: Fireside Chat Location: Miami, FL

Citi's 2026 Global Healthcare Conference Date and Time: December 1, 2026 at 1:00 p.m. ET Format: Fireside Chat Location: Miami, FL

Piper Sandler 38th Annual Healthcare Conference Date and Time: December 2, 2026 at 1:30 p.m. ET Format: Fireside Chat Location: New York, NY

Live webcasts and recordings of these presentations will be available, as permitted by the event host, in the Events and Presentations section of Olema’s investor relations website at ir.olema.com.
About Olema Oncology Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.

Media and Investor Relations Contact Courtney O’Konek Vice President, Corporate Communications Olema Oncology media@olema.com

Frequently Asked Questions

What conferences will Olema Oncology attend?

Olema will attend the Evercore, Citi's Global, and Piper Sandler conferences.

When is Olema's presentation at the Evercore Conference?

The Evercore Healthcare Conference is on November 30, 2026.

What is Olema's lead product candidate?

Olema's lead candidate is palazestrant, an estrogen receptor antagonist.

Where is Olema Oncology headquartered?

Olema Oncology is headquartered in San Francisco, California.

Last updated: Nov 16, 2026